Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Status:
Completed
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of entinostat in treating pediatric
patients with solid tumors that have come back or have not responded to treatment. Entinostat
may block some of the enzymes needed for cell division and it may help to kill tumor cells.